The Claim
During the weight-maintenance phase in adults with overweight or obesity, gastrointestinal adverse events occur more frequently with anti-obesity medications than with placebo, while serious adverse events occur at similar rates between the two groups.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In adults with overweight or obesity who are maintaining their weight, anti-obesity medications cause more gastrointestinal side effects than placebo, but they do not cause more serious side effects.
See the scientific wording
Gastrointestinal adverse events are more common with anti-obesity medications than with placebo during the weight-maintenance phase in adults with overweight or obesity, but serious adverse events are not significantly increased.
These medications slow down the stomach and intestines and irritate the lining of the gut, causing nausea, bloating, and diarrhea, but they do not trigger severe tissue damage or systemic inflammation that leads to serious health problems.
What the research says
1 studyPeople who take weight-loss pills after losing weight are more likely to get stomach problems like nausea or diarrhea than those taking a sugar pill, but they don’t have more serious health dangers. The study found this to be true.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.